Chronic Disease Management Market Size, Share and Growth Outlook, 2026

Chronic Disease Management Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Chronic Disease Management Market size is forecast to increase from $7.63 Billion in 2026 to $19.44 Billion in 2034 at a CAGR of 12.4% between 2026 and 2034.

The Chronic Disease Management market report provides detailed analysis and outlook of Chronic Disease Management segments including By Solution Type (Software & Cloud Platforms, Services ), By Deployment Mode (Cloud-Based, On-Premise), By Disease Indication (Cardiovascular Diseases, Diabetes, Cancer, Chronic Obstructive Pulmonary Disease, Arthritis and Musculoskeletal Disorders), By End-User (Healthcare Providers, Healthcare Payers, Patients) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Chronic Disease Management Industry Overview

Artificial Intelligence Transforming Remote Chronic Care Delivery

The Chronic Disease Management industry is undergoing a major transformation as healthcare providers increasingly adopt artificial intelligence, remote monitoring technologies, and data-driven clinical decision support systems to improve long-term patient outcomes. A significant development in this space is Hartford HealthCare’s strategic partnership with Cadence, an AI-powered chronic care management company. Through this collaboration, Hartford HealthCare deployed the Clinical Intelligence platform across its Remote Care network, integrating connected in-home monitoring devices with supervised AI agents. The platform continuously tracks vital signs and daily biometric measurements from patients managing hypertension, type 2 diabetes, and heart failure. Advanced algorithms evaluate patient data against established clinical guidelines to identify deterioration risks and automatically generate evidence-based medication adjustment recommendations. This approach enables healthcare teams to intervene earlier, improve disease control, and support aging populations requiring ongoing clinical oversight outside traditional care settings.

EHR-Integrated Decision Support Improving Clinical Outcomes

Healthcare organizations are increasingly leveraging electronic health record integration to streamline chronic disease management workflows and enhance treatment consistency. Digital health research organization HITLAB completed a comprehensive validation review of MedsEngine, an EHR-integrated clinical decision support platform designed for longitudinal disease management. Utilizing secure FHIR interoperability frameworks, the application transforms existing patient records into real-time, guideline-directed therapeutic recommendations. Clinical findings demonstrated that providers using the platform achieved verified high blood pressure control in more than 90% of participating patients within fewer than two office visits. In addition to improving hypertension outcomes, the system significantly reduced manual documentation requirements associated with diabetes and cholesterol management programs. The growing adoption of interoperable clinical intelligence platforms highlights the industry's focus on automating care pathways, reducing administrative burden, and supporting evidence-based treatment decisions across chronic disease populations.

Personalized Continuous Care Models Expanding Patient Engagement

Patient-centered chronic care management models are evolving beyond episodic healthcare interactions toward continuous, digitally enabled engagement. Medical AI company Counsel Health expanded its physician-supervised, AI-first platform to include dedicated chronic disease management services for patients living with obesity, hypertension, and high cholesterol. The platform incorporates a comprehensive view of each patient's health profile, including medication records, laboratory results, and longitudinal medical history. Through continuous communication with assigned clinical teams, patients receive ongoing support, monitoring, and treatment optimization. The model also delivers measurable economic benefits, with engaged members reporting average annual savings of $381 through improved disease management and care coordination. As healthcare systems increasingly prioritize preventive care, remote monitoring, and personalized treatment strategies, AI-powered chronic disease management platforms are becoming essential tools for improving clinical outcomes while enhancing patient engagement and healthcare efficiency.

Chronic Disease Management Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Chronic Disease Management market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Veradigm Inc., ScienceSoft USA Corporation, Siemens Healthineers, Infosys Limited, Teladoc Health, Inc., Pegasystems Inc., Health Catalyst, Inc., Epic Systems Corporation, ZeOmega Inc., Wellcentive, Inc. (Philips). The Chronic Disease Management market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Chronic Disease Management industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Chronic Disease Management Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Chronic Disease Management companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Chronic Disease Management markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Chronic Disease Management Market Competitive Benchmarking and Company Analysis

Leading companies in Chronic Disease Management industry include- Veradigm Inc., ScienceSoft USA Corporation, Siemens Healthineers, Infosys Limited, Teladoc Health, Inc., Pegasystems Inc., Health Catalyst, Inc., Epic Systems Corporation, ZeOmega Inc., Wellcentive, Inc. (Philips). The Chronic Disease Management market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Chronic Disease Management Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Chronic Disease Management market remains one of the strongest-performing segments in the country.
The US Chronic Disease Management Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Chronic Disease Management market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Chronic Disease Management industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Chronic Disease Management markets

Canada's strong Chronic Disease Management sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Chronic Disease Management market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Chronic Disease Management Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Chronic Disease Management market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Chronic Disease Management population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Chronic Disease Management industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Chronic Disease Management market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Chronic Disease Management sales through 2034

France Chronic Disease Management companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Chronic Disease Management Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Chronic Disease Management distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Chronic Disease Management Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Chronic Disease Management market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Chronic Disease Management industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Chronic Disease Management industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Chronic Disease Management Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Chronic Disease Management market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Chronic Disease Management market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Chronic Disease Management Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Chronic Disease Management Market Segmentation

By Solution Type
Software & Cloud Platforms
Services
By Deployment Mode
Cloud-Based
On-Premise
By Disease Indication
Cardiovascular Diseases
Diabetes
Cancer
Chronic Obstructive Pulmonary Disease
Arthritis and Musculoskeletal Disorders
By End-User
Healthcare Providers
Healthcare Payers
Patients

Top Companies in Chronic Disease Management Industry

Veradigm Inc.
ScienceSoft USA Corporation
Siemens Healthineers
Infosys Limited
Teladoc Health, Inc.
Pegasystems Inc.
Health Catalyst, Inc.
Epic Systems Corporation
ZeOmega Inc.
Wellcentive, Inc. (Philips)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025